ReviewExperimental and therapeutic medicine2022
Lung neuroendocrine tumors: A systematic literature review (Review).
Review in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- CDR-Informed Graph Neural Network for Plasma Metabolomics in Lung Cancer and Pulmonary Neuroendocrine Neoplasms.International journal of molecular sciences · 2026Article
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Typical carcinoid tumor originating from the tracheal carina managed with carinal resection and neo-carinal bronchoplastic reconstruction: a case report.Journal of cardiothoracic surgery · 2026Article
- Enhancing Diagnostic Pathways for Bronchopulmonary Neuroendocrine Tumors: Assessment of the South Wales Neuroendocrine Tumor Service Transformation.Thoracic cancer · 2026Article
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
- High cereblon expression in neuroendocrine cancer confers vulnerability to GSPT1 molecular glue degrader.Experimental hematology & oncology · 2025Article
- Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States.Annals of surgery · 2025Article
- Neuroendocrine neoplasms of the lung: The latest updates.World journal of clinical oncology · 2025Review
- Application of Radiomics for Differentiating Lung Neuroendocrine Neoplasms.Diagnostics (Basel, Switzerland) · 2025Article
- A Rare Case of Neonatal Desmoid Tumor Leading to Severe Aortic Coarctation: Review of Literature and Case Report.Life (Basel, Switzerland) · 2025Review
- SurvSig: Harnessing gene expression signatures to uncover heterogeneity in lung neuroendocrine neoplasms.Computational and structural biotechnology journal · 2025Article
- A case of carcinoid syndrome after CT guided lung biopsy of a neuroendocrine tumor.Radiology case reports · 2024Article
- Uncommon Metastasis of a Large-Cell Neuroendocrine Carcinoma From the Lungs to the Buccal Palatal Region.Cureus · 2024Article
- Application of Artificial Intelligence in Neuroendocrine Lung Cancer Diagnosis and Treatment: A Systematic Review.Cureus · 2024Review
- Article
- Article
- The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer.International journal of molecular sciences · 2023Review
- Article
- Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report.Translational cancer research · 2022Article
- Bronchoscopic removal of bronchial carcinoid tumors: Case series and literature review.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) can have multiple localizations in the human body however, most often, it appears in the in thorax at tracheobronchial tree and the thymus. NETs are a group of tumors with heterogenous malignancy that evolve from neuroendocrine cells, with the lung being the second target organ after the gastrointestinal tract. These rare tumors are usually asymptomatic and non-functional with little information regarding incidence in the specialty literature. The main purpose of this review, was the analysis of the available literature in all aspects while mainly focusing on molecular diagnosis data and secondly, by using this molecular landscape to establish a differentiation of lung neuroendocrine tumors (LNETs). By analyzing the literature, new data were revealed regarding histological evaluation, genetic aberrations, prognosis depending on the type of LNET and therapeutic options that derive from these. Efficient management of these tumors is essential in the handling of symptoms and increase in life expectancy, especially in patients with functional tumors. Histological differentiation of LNETs is important in establishing proper therapeutic options and prognosis. Combined types of LNETs remain a controversial topic of discussion regarding diagnosis and treatment, a topic on which further studies are required in order to improve diagnosis in this group of tumors with heterogenous malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.